(Total Views: 656)
Posted On: 07/25/2021 10:51:59 AM
Post# of 66
MOST UNDERVALUED IMMUNO-ONCOLOGY COMPANY
Justification FOR Immediate Significant Valuation Increase
•Jul 12, 2021 at 11:00 AM EDT- H.C. WAINWRIGHT FIRESIDE CHAT WITH PHIO PHARMACEUTICALS https://journey.ct.events/view/968a8554-b0b5-...2bb0c9483b
• HC WAINWRIGHT CHAT Highlights Valuation comparisons with Pre-Clinic Stage Peers
CELLECTIS (NASDA SYMBOL: CLLS) Market Cap $600 million
INSTIL BIO (NASDAQ SYMBOL: TIL) Market Cap $2.5 billion
Lyell Immunopharma (SYMBOL: LYEL) Market Cap $4 billion
Phio Pharmaceuticals (SYMBOL: PHIO) Market Cap $25 million
• Highly Successful Collaboration Studies with: Iovance, Gustave Rousey, Agonox, et.al.
• $32 million in CASH
• $1.90 PPS is below Book Value
• Analyst Vernon Bernardino, Director at HC WAINWRIGHT rating BUY with Target $6
• Q1:2022 PH-762 CLINICAL TRIAL US & EU
• FOLLOW SMART MONEY- PHIO Employees Buy in @ $2.5 to $3
• 109 Patents 42 International Patents
AGAINST
• 4 Reverse Stock Splits totaling 1:1,000 in last 6 years = most hated publicly traded company
• Low Investor interest
FULL DISCLOSURE:
Michael P May credentials: MBA, BS Chemical Engineering, 1997-2007 NASD Reg Series 7,
Adjunct Professor of Investments 1998 – 2018 Walsh University
He owns PHIO shares and is accumulating since inception 8 years ago.
Justification FOR Immediate Significant Valuation Increase
•Jul 12, 2021 at 11:00 AM EDT- H.C. WAINWRIGHT FIRESIDE CHAT WITH PHIO PHARMACEUTICALS https://journey.ct.events/view/968a8554-b0b5-...2bb0c9483b
• HC WAINWRIGHT CHAT Highlights Valuation comparisons with Pre-Clinic Stage Peers
CELLECTIS (NASDA SYMBOL: CLLS) Market Cap $600 million
INSTIL BIO (NASDAQ SYMBOL: TIL) Market Cap $2.5 billion
Lyell Immunopharma (SYMBOL: LYEL) Market Cap $4 billion
Phio Pharmaceuticals (SYMBOL: PHIO) Market Cap $25 million
• Highly Successful Collaboration Studies with: Iovance, Gustave Rousey, Agonox, et.al.
• $32 million in CASH
• $1.90 PPS is below Book Value
• Analyst Vernon Bernardino, Director at HC WAINWRIGHT rating BUY with Target $6
• Q1:2022 PH-762 CLINICAL TRIAL US & EU
• FOLLOW SMART MONEY- PHIO Employees Buy in @ $2.5 to $3
• 109 Patents 42 International Patents
AGAINST
• 4 Reverse Stock Splits totaling 1:1,000 in last 6 years = most hated publicly traded company
• Low Investor interest
FULL DISCLOSURE:
Michael P May credentials: MBA, BS Chemical Engineering, 1997-2007 NASD Reg Series 7,
Adjunct Professor of Investments 1998 – 2018 Walsh University
He owns PHIO shares and is accumulating since inception 8 years ago.
(0)
(0)
